Logo image of PRLD

PRELUDE THERAPEUTICS INC (PRLD) Stock Fundamental Analysis

USA - NASDAQ:PRLD - US74065P1012 - Common Stock

0.9848 USD
-0.03 (-2.5%)
Last: 9/19/2025, 8:00:01 PM
0.99 USD
+0.01 (+0.53%)
After Hours: 9/19/2025, 8:00:01 PM
Fundamental Rating

2

PRLD gets a fundamental rating of 2 out of 10. The analysis compared the fundamentals against 541 industry peers in the Biotechnology industry. PRLD scores quite bad on profitability, while its financial health is fine. Not spectacular, but in line with the averages. PRLD is valued expensive and it does not seem to be growing.


Dividend Valuation Growth Profitability Health

Quickly go to:

0

1. Profitability

1.1 Basic Checks

In the past year PRLD has reported negative net income.
In the past year PRLD has reported a negative cash flow from operations.
PRLD had negative earnings in each of the past 5 years.
In the past 5 years PRLD always reported negative operating cash flow.
PRLD Yearly Net Income VS EBIT VS OCF VS FCFPRLD Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2018 2019 2020 2021 2022 2023 2024 -20M -40M -60M -80M -100M

1.2 Ratios

PRLD has a Return On Assets of -72.46%. This is in the lower half of the industry: PRLD underperforms 63.59% of its industry peers.
The Return On Equity of PRLD (-96.74%) is comparable to the rest of the industry.
Industry RankSector Rank
ROA -72.46%
ROE -96.74%
ROIC N/A
ROA(3y)-56.23%
ROA(5y)-46.15%
ROE(3y)-69.07%
ROE(5y)-54.62%
ROIC(3y)N/A
ROIC(5y)N/A
PRLD Yearly ROA, ROE, ROICPRLD Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2018 2019 2020 2021 2022 2023 2024 -50 -100 -150

1.3 Margins

PRLD does not have Profit Margin and Operating Margin and Gross Margin available, so we won't be analyzing them here.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM N/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
PRLD Yearly Profit, Operating, Gross MarginsPRLD Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2018 2019 2020 2021 2022 2023 2024 -500 -1K -1.5K

More info and screens

5

2. Health

2.1 Basic Checks

PRLD does not have a ROIC to compare to the WACC, probably because it is not profitable.
The number of shares outstanding for PRLD has been increased compared to 1 year ago.
The number of shares outstanding for PRLD has been increased compared to 5 years ago.
PRLD has a worse debt/assets ratio than last year.
PRLD Yearly Shares OutstandingPRLD Yearly Shares OutstandingYearly Shares Outstanding 2018 2019 2020 2021 2022 2023 2024 10M 20M 30M 40M 50M
PRLD Yearly Total Debt VS Total AssetsPRLD Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2018 2019 2020 2021 2022 2023 2024 100M 200M 300M

2.2 Solvency

Based on the Altman-Z score of -5.73, we must say that PRLD is in the distress zone and has some risk of bankruptcy.
The Altman-Z score of PRLD (-5.73) is worse than 62.48% of its industry peers.
PRLD has no outstanding debt. Therefor its Debt/Equity and Debt/FCF ratios are 0 and belong to the best of the industry.
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Altman-Z -5.73
ROIC/WACCN/A
WACC9.66%
PRLD Yearly LT Debt VS Equity VS FCFPRLD Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2018 2019 2020 2021 2022 2023 2024 0 100M -100M 200M

2.3 Liquidity

A Current Ratio of 5.30 indicates that PRLD has no problem at all paying its short term obligations.
PRLD has a Current ratio (5.30) which is in line with its industry peers.
A Quick Ratio of 5.30 indicates that PRLD has no problem at all paying its short term obligations.
PRLD has a Quick ratio of 5.30. This is comparable to the rest of the industry: PRLD outperforms 58.96% of its industry peers.
Industry RankSector Rank
Current Ratio 5.3
Quick Ratio 5.3
PRLD Yearly Current Assets VS Current LiabilitesPRLD Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2018 2019 2020 2021 2022 2023 2024 50M 100M 150M 200M 250M

More info and screens

3

3. Growth

3.1 Past

PRLD shows a strong growth in Earnings Per Share. In the last year, the EPS has been growing by 8.38%, which is quite good.
EPS 1Y (TTM)8.38%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%10.87%
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A

3.2 Future

The Earnings Per Share is expected to grow by 7.99% on average over the next years.
PRLD is expected to show a strong growth in Revenue. In the coming years, the Revenue will grow by 62.04% yearly.
EPS Next Y14.1%
EPS Next 2Y17.68%
EPS Next 3Y14.63%
EPS Next 5Y7.99%
Revenue Next Year-100%
Revenue Next 2Y-41.42%
Revenue Next 3Y-25.99%
Revenue Next 5Y62.04%

3.3 Evolution

PRLD Yearly Revenue VS EstimatesPRLD Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2024 2029 2030 2031 2032 50M 100M 150M
PRLD Yearly EPS VS EstimatesPRLD Yearly EPS VS EstimatesYearly EPS VS Estimates 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 2031 2032 0 -1 -2 -3

More info and screens

0

4. Valuation

4.1 Price/Earnings Ratio

The Price/Earnings Ratio is negative for PRLD. In the last year negative earnings were reported.
Besides the negative Price/Earnings Ratio, also the Forward Price/Earnings Ratio is negative for PRLD. No positive earnings are expected for the next year.
Industry RankSector Rank
PE N/A
Fwd PE N/A
PRLD Price Earnings VS Forward Price EarningsPRLD Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 20 40 60

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
PRLD Per share dataPRLD EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 1 -1 2

4.3 Compensation for Growth

PRLD's earnings are expected to grow with 14.63% in the coming years. This may justify a more expensive valuation.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y17.68%
EPS Next 3Y14.63%

More info and screens

0

5. Dividend

5.1 Amount

No dividends for PRLD!.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

PRELUDE THERAPEUTICS INC

NASDAQ:PRLD (9/19/2025, 8:00:01 PM)

After market: 0.99 +0.01 (+0.53%)

0.9848

-0.03 (-2.5%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)08-14 2025-08-14/bmo
Earnings (Next)11-04 2025-11-04/bmo
Inst Owners44.84%
Inst Owner Change-13.43%
Ins Owners11.38%
Ins Owner Change24.62%
Market Cap55.74M
Analysts80
Price Target3.57 (262.51%)
Short Float %1.91%
Short Ratio3.3
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)2
Avg EPS beat(2)15.12%
Min EPS beat(2)10.65%
Max EPS beat(2)19.59%
EPS beat(4)3
Avg EPS beat(4)10.12%
Min EPS beat(4)-4.88%
Max EPS beat(4)19.59%
EPS beat(8)7
Avg EPS beat(8)13.26%
EPS beat(12)11
Avg EPS beat(12)10.59%
EPS beat(16)11
Avg EPS beat(16)6.11%
Revenue beat(2)N/A
Avg Revenue beat(2)N/A
Min Revenue beat(2)N/A
Max Revenue beat(2)N/A
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)-6.67%
PT rev (3m)-6.67%
EPS NQ rev (1m)0%
EPS NQ rev (3m)0%
EPS NY rev (1m)0%
EPS NY rev (3m)14.31%
Revenue NQ rev (1m)N/A
Revenue NQ rev (3m)N/A
Revenue NY rev (1m)N/A
Revenue NY rev (3m)N/A
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S 7.96
P/FCF N/A
P/OCF N/A
P/B 0.42
P/tB 0.42
EV/EBITDA N/A
EPS(TTM)-1.64
EYN/A
EPS(NY)-1.04
Fwd EYN/A
FCF(TTM)-1.83
FCFYN/A
OCF(TTM)-1.82
OCFYN/A
SpS0.12
BVpS2.32
TBVpS2.32
PEG (NY)N/A
PEG (5Y)N/A
Profitability
Industry RankSector Rank
ROA -72.46%
ROE -96.74%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM N/A
FCFM N/A
ROA(3y)-56.23%
ROA(5y)-46.15%
ROE(3y)-69.07%
ROE(5y)-54.62%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3YN/A
ROICexcg growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score4
Asset Turnover0.04
Health
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr 43.12%
Cap/Sales 10.91%
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 5.3
Quick Ratio 5.3
Altman-Z -5.73
F-Score4
WACC9.66%
ROIC/WACCN/A
Cap/Depr(3y)190.81%
Cap/Depr(5y)187.88%
Cap/Sales(3y)N/A
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)8.38%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%10.87%
EPS Next Y14.1%
EPS Next 2Y17.68%
EPS Next 3Y14.63%
EPS Next 5Y7.99%
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A
Revenue Next Year-100%
Revenue Next 2Y-41.42%
Revenue Next 3Y-25.99%
Revenue Next 5Y62.04%
EBIT growth 1Y-5.61%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year-15.26%
EBIT Next 3YN/A
EBIT Next 5YN/A
FCF growth 1Y6.26%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y3.9%
OCF growth 3YN/A
OCF growth 5YN/A